Protagonist surges on FDA approval of J&J psoriasis pill
ICOTYDE approval triggers $50M milestone payment as oral drug challenges AbbVie's dominance
Protagonist Therapeutics shares surged to within striking distance of their 52-week high on Thursday after the U.S. Food and Drug Administration approved ICOTYDE, a once-daily psoriasis pill developed in partnership with Johnson & Johnson that threatens to reshape the competitive landscape for inflammatory disease treatments.
The FDA cleared ICOTYDE (icotrokinra) for moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older, triggering an immediate $50 million milestone payment to Protagonist. The Newark, California-based biotechnology company remains eligible for up to $580 million in additional regulatory and sales milestone payments, plus tiered royalties ranging from 6% to 10% on global net sales.
Protagonist's stock traded as high as $99.44 on Thursday, just shy of its 52-week peak of $99.31, with volume running at roughly 2.5 times the daily average. The shares closed at $97.09 on Wednesday and have rallied more than 140% over the past year, giving the company a market capitalization of approximately $6.2 billion.
The approval marks a significant validation for Protagonist's peptide platform technology and establishes ICOTYDE as the first oral interleukin-23 (IL-23) receptor antagonist to reach the market. In clinical trials involving 2,500 patients across five Phase 3 studies, approximately 70% of patients achieved clear or almost clear skin as measured by the Investigator's Global Assessment score by week 16. The drug demonstrated a safety profile comparable to placebo through the first 16 weeks of treatment.
"With the FDA approval of ICOTYDE, Johnson & Johnson is setting a new standard for the treatment of moderate-to-severe plaque psoriasis," said Jennifer Taubert, executive vice president and worldwide chairman of Innovative Medicine at Johnson & Johnson. "We're proud to bring this game-changing innovation to the market, marking a transformative shift in plaque psoriasis management."
The approval creates a new competitive dynamic in the psoriasis market, which analysts project could grow from $35.85 billion in 2025 to $57.32 billion by 2034. ICOTYDE will compete directly with AbbVie's dominant Skyrizi franchise, which generated $17.6 billion in sales in 2025 and is expected to grow 23% this fiscal year. Skyrizi is an injectable IL-23 inhibitor, while ICOTYDE offers patients the convenience of a once-daily oral pill.
The oral formulation could prove particularly disruptive as dermatologists and patients seek alternatives to injectable biologics. Johnson & Johnson's oral IL-23 receptor blocker enters a market where AbbVie's Humira—once the world's bestselling drug—has seen sales plunge approximately 50% year-over-year in the fourth quarter of 2025 amid aggressive biosimilar competition. The global Humira market is projected to decline from $10.34 billion in 2024 to $4.11 billion by 2030.
Analysts have begun positioning for ICOTYDE's commercial potential, with Jefferies setting a price target of $121 for Protagonist shares. According to analyst projections, peak sales for ICOTYDE are estimated between $5.5 billion and $7.5 billion. Of the 12 analysts covering Protagonist, 11 rate the stock a buy or strong buy, with a consensus price target of $107.83.
The financial structure of the Johnson & Johnson partnership provides meaningful near-term revenue for Protagonist, which reported $46 million in trailing twelve-month revenue and negative earnings per share of $2.05. The milestone payments and royalties could help the company fund its broader pipeline, which includes additional peptide-based therapeutics targeting gastrointestinal and hematologic disorders.
Johnson & Johnson retains exclusive worldwide rights to develop and commercialize ICOTYDE, leveraging its established immunology commercial infrastructure that already includes products like Stelara and Tremfya. The company launched the ICOTYDE withMe patient support program to help patients access the treatment, including cost support options.
"The approval of ICOTYDE represents a pivotal moment for people with plaque psoriasis," said John Reed, executive vice president of research and development at Johnson & Johnson's Innovative Medicine division. "ICOTYDE is a fundamentally different treatment with the potential to redefine what physicians and patients can expect from psoriasis treatment."
The approval also validates the broader therapeutic potential of targeted oral peptides, a modality that has struggled to gain regulatory approval historically. Protagonist's success could open the door for additional oral peptide treatments in other inflammatory diseases, potentially expanding the company's partnership opportunities and pipeline value.
For investors, the key catalysts to watch include ICOTYDE's commercial launch timing, early prescription data, and potential label expansions into related inflammatory conditions such as psoriatic arthritis. The drug's performance will be closely scrutinized by both AbbVie investors monitoring threats to Skyrizi and by biotechnology analysts assessing the viability of the oral peptide approach.